相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2016)
New Genetic Markers for Prostate Cancer
Michael S. Leapman et al.
UROLOGIC CLINICS OF NORTH AMERICA (2016)
Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk
Eric A. Klein et al.
UROLOGY (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
Dipen J. Parekh et al.
EUROPEAN UROLOGY (2015)
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer
Jennifer Cullen et al.
EUROPEAN UROLOGY (2015)
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer
Kosj Yamoah et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy
Robert B. Den et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling
Eric A. Klein et al.
EUROPEAN UROLOGY (2014)
Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer
Gisele H. J. M. Leyten et al.
EUROPEAN UROLOGY (2014)
Multicenter European External Validation of a Prostate Health Index-based Nomogram for Predicting Prostate Cancer at Extended Biopsy
Giovanni Lughezzani et al.
EUROPEAN UROLOGY (2014)
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Serum Isoform [-2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2-10 ng/ml: A Multicentric European Study
Massimo Lazzeri et al.
EUROPEAN UROLOGY (2013)
Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy
Stephen J. Freedland et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study
Grant D. Stewart et al.
JOURNAL OF UROLOGY (2013)
The Role of Sarcosine Metabolism in Prostate Cancer Progression
Amjad P. Khan et al.
NEOPLASIA (2013)
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
J. Cuzick et al.
BRITISH JOURNAL OF CANCER (2012)
A Panel of TMPRSS2:ERG Fusion Transcript Markers for Urine-Based Prostate Cancer Detection with High Specificity and Sensitivity
Phuong-Nam Nguyen et al.
EUROPEAN UROLOGY (2011)
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
William J. Catalona et al.
JOURNAL OF UROLOGY (2011)
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Jack Cuzick et al.
LANCET ONCOLOGY (2011)
Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection
Flip H. Jansen et al.
EUROPEAN UROLOGY (2010)
PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial
Sheila M. J. Aubin et al.
JOURNAL OF UROLOGY (2010)
Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer
Heidi Schwarzenbach et al.
CLINICAL CANCER RESEARCH (2009)
Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens
Jennifer Maki et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
Alexander Haese et al.
EUROPEAN UROLOGY (2008)
A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy
Tohru Nakagawa et al.
PLOS ONE (2008)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
Leonard S. Marks et al.
UROLOGY (2007)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
分享论文
